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Cancer patients undergoing Doxorubicin (DOX) treatment are susceptible to acute and
chronic cardiac anomalies, including aberrant arrhythmias, ventricular dysfunction, and
heart failure. To stratify patients at high risk for DOX -related heart failure (CHF), diagnostic
techniques have been sought. While echocardiography is used for monitoring LVEF and LV
volumes due to its wide-availability and cost-efficiency, it may not identify early stages of the
initiation of DOX-induced systolic heart failure. To address these limitations, PET tracers
could also provide noninvasive assessment of early and reversible metabolic changes of
the myocardium.
Objective
Herein, we report a preliminary investigation of 68Ga-Galmydar potential to monitor Dox-
induced cardiomyopathy in vivo, ex vivo, and in cellulo employing both nuclear- and optical
imaging.
Methods and results
To assess 68Ga-Galmydar ability for monitoring DOX-induced cardiomyopathy, microPET
imaging was performed 5 d post treatment of rats either with a single dose of DOX (15 mg/
kg) or vehicle as a control (saline) and images were co-registered for anatomical reference
using CT. Following tail-vein injection of the radiotracer in rats at 60 min, micro-PET/CT
static scan (10 min acquisition), 68Ga-Galmydar demonstrated 1.91-fold lower uptake in
hearts of DOX-treated (standard uptake value; SUV: 0.92, n = 3) rats compared with their
vehicle treated (SUV: 1.76, n = 3) control counterparts. For correlation of PET imaging data,
post-imaging quantitative biodistribution studies were also performed, wherein excised
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organs were counted for γ activity, and normalized to injected dose. The post imaging phar-
macokinetic data also demonstrated heart uptake values of 2.0 fold lower for DOX treated
rats(%ID/g; DOX: 0.44 ± 0.1, n = 3) compared to their vehicle-treated controls (%ID/g; Con-
trol: 0.89 ± 0.03, n = 3, p = 0.04). Employing the fluorescent traits of Galmydar, live cell fluo-
rescence imaging indicated a gradual decrease in uptake and retention of Galmydar within
mitochondria of H9c2 cells following DOX-treatment, while indicating dose-dependent and
time-dependent uptake profiles. Following depolarization of electronegative transmembrane
gradients at the mitochondrial membrane, the uptake of the probe was decreased in H9c2
cells, and the uptake profiles were found to be identical, using both fluorescence and radio-
tracer bioassays. Finally, the decreased uptake of the metalloprobe in H9c2 cells also corre-
lated with caspase-3 expression resulting from DOX-induced cardiotoxicity and cell death.
Conclusions
68Ga-Galmydar could provide a noninvasive assessment of DOX-related and likely revers-
ible metabolic changes at earliest stages. Further studies with other chemotherapeutics
(potentially capable of inducing cardiomyopathy) are underway.
Introduction
Doxorubicin (DOX; Adriamycin), an anthracycline analogue is a highly versatile chemothera-
peutic drug, widely deployed in medical oncology for treating patients with broad spectrum of
cancers[1–13], such as acute lymphoblastic leukemia (ALL), acute myeloblastic leukemia
(AML), multiple myeloma, neuroblastoma, breast cancer, ovarian cancer, small cell lung cancer,
thyroid cancer, head and neck cancer, Hodgkin lymphoma, bone sarcoma, liver, and kidney
cancer. Among its mechanism of action, DOX has been postulated to induce its antimitotic and
anti-tumor activity by intercalating between DNA base pairs, inhibiting DNA transcription,
concomitantly halting protein synthesis, and triggering over-production of free-radical reactive
oxygen species (ROS) thus inducing cytotoxic effects indiscriminately including cardiotoxicity
[14]. Therefore, the clinical utility of DOX, and other chemotherapeutics in this class of drugs is
somewhat curtailed by their putative dose-dependent cardiotoxicity, resulting from the sensitiv-
ity of myocardium cells to oxidative stress[15]. The irreversible side-effects of DOX treatment
in patients also include dilated cardiomyopathy [15]. These effects are further exacerbated by
the fact that the myocardium tissue lacks expression of the adenosine binding cassette (ABC)
family of drug transporters, such as Pgp and BCRP [16], which are poised to excrete recognized
substrates from targeted tissues thus diminishing cytotoxic effects [15]. Noticeably, symptoms
of DOX-induced cardiomyopathy can manifest in patients during or after DOX treatment,
pointing to the exigency for a diagnostic probe to discern cardiac alterations in the subclinical
stages, in order to mitigate permanent damage[17]. Current diagnostic techniques, such as mul-
tigated acquisition scan (MUGA) and echocardiography provide information about DOX
related decrease in left ventricular function that may already reflect irreversible cardiac damage
[17]. Therefore, mechanistic pathways mediating DOX-induced cardiomyopathy have been
intensely debated, including a role of DOX metabolism in the mitochondria [18, 19]. Earlier, we
have reported that 67/68Ga-Galmydar, could be a useful myocardial perfusion molecular imaging
(MPI) agent [20]. Importantly, Galmydar is a cationic, metalloprobe having a fairly uniform dis-
tribution of a delocalized positive charge on its molecular surface [21] with overall octahedral
geometry (Fig 1; See Analytical Characterization: S1–S3 Figs, S1 and S2 Tables). Literature
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precedents also indicate that mitochondrial dysfunction could be “an early” or “the earliest”
indicator of DOX-induced cardiomyopathy [15], wherein downstream activation of effector
caspases mediates cell apoptosis [22]. Therefore, molecular imaging agents capable of offering
noninvasive and specific detection of mitochondrial function in vivo have been sought. To
accomplish this objective, single photon emission computed tomography (SPECT) imaging
probes, such as 99mTc-Sestamibi (MIBI: methoxy-isobutylisonitrile) has been investigated for
detection of DOX-induced cardiomyopathy. However, the data from 99mTc-Sestamibi studies
are conflicting. While the cell assays [23] and human studies [24] showed decreased cardiac-
uptake of 99mTc-Sestamibi upon DOX treatment, animal studies [25] conversely revealed
enhanced uptake of the radiotracer in myocardium following DOX treatment. While beneficial,
99mTc-incorporated SPECT imaging agents have also inherent limitations, including the con-
tinuing threat of serious shortages of 99mMo/99mTc-generators [26, 27]. Additionally, current
SPECT tracers also suffer from shortcomings in pharmacokinetics, redistribution of the radio-
tracer to non-targeted tissues over time, non-linearity of uptake at elevated blood flow (the
“roll-off” phenomenon), and low sensitivity [28]. By comparison, positron emission tomogra-
phy (PET) imaging provides technical advantages, including higher spatial resolution, improved
attenuation correction, and the capability to perform quantitative measurements at the peak of
stress [29]. Herein, we demonstrate that myocardial uptake profiles of 68Ga-Galmydar could
provide the earliest indication of DOX-induced cardiomyopathy in vivo, while also assessing
correlations of myocardial radiotracer uptake with status of mitochondrial potential, using opti-
cal imaging at a single cell level. Overall, these data indicate that 68Ga-Galmydar could provide a
potential diagnostic tool for noninvasive assessment of DOX-induced myocardial dysfunction,
while also enabling monitoring of oxidative-stress induced apoptosis.
Material and methods
All reagents were purchased from Sigma-Aldrich (St. Louis, MO), unless otherwise stated.
1HNMR and proton-decoupled 13C NMR spectra were recorded on either 300MHz or
400MHzspectrometer (Varian); chemical shifts are reported in δ (ppm) with reference to
TMS. Mass spectra were obtained from the Washington University Resource for Biomedical
Fig 1. (A) Crystal structure of Galmydar. (B) Chemical Structure. (C) Space Filling Model showing distribution of charge on the molecular surface.
https://doi.org/10.1371/journal.pone.0215579.g001
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and Bioorganic Mass Spectrometry using samples diluted in 50/50 methanol/water containing
0.1% formic acid and analyzed via HRESI. Elemental analyses were performed by Galbraith Labo-
ratories, Knoxville, TN. HPLC analysis was performed with a Waters System 600 equipped with
dual λ-detector 2487 (280 and 214 nm) and a γ-detector (Bioscan) for identification of radiopeaks.
Galmydar and its 68Ga-radiolabeled counterpart were assessed for purity on a C-18 reversed-
phase column (Vydac TP, 10 μm, 300 Å) using an eluent gradient of ethanol and saline (20% etha-
nol in saline from 0–5 min, 20–90% ethanol in saline from 5–25 min, 90% ethanol in saline from
25–30 min, 100% ethanol from 30–35 min, and 100% saline from 35–40 min; at a flow of 2 mL/
min). Radiochemical purity was also determined on C-18 plates, employing a mobile eluent mix-
ture of 90/10 ethanol/saline, using a radio-TLC (Bioscan System 200 Image Scanner).
Chemistry
The precursor heptadentate ligand, unlabeled Galmydar, and 68Ga-Glamydar were synthesized
as described earlier [20] and with slight modifications, and are briefly described below:
Chemical synthesis. For characterization of the radiotracer, the unlabeled Galmydar was
synthesized by treating the precursor heptadentate ligand dissolved in ethanol with a dropwise
addition of gallium(III) acetylacetonate dissolved in ethanol, involving the ligand exchange
reaction described earlier, and spectroscopically and analytically characterized[20]. 1H NMR
(300 MHz, DMSO-d6) δ: 0.79 (s, 6H), 0.96 (s, 6H), 1.30–1.33 (dd, 12H), 2.63 (d, 2H), 2.79 (d,
4H), 2.94 (br, s, 2H), 3.61–3.75 (m, 4H), 4.63 (sept, 2H), 4.79 (br, s, 2H), 6.62 (t, 2H), 6.87 (d,
2H), 7.04 (d, 2H), 8.18 (s, 2H); 13C NMR (75 MHz, DMSO-d6) δ: 22.0, 22.1, 22.2, 26.2, 35.6,
47.7, 59.2, 68.9, 69.5, 115.7, 119.2, 119.5, 125.8, 148.7, 158.1, 170.3; MS (HRESI) Calcd for
[C32H48N4O4Ga]
+: 621.2926, found: m/z = 621.2930; and Calcd for [13C32H48N4O4Ga]+:
622.2959, found: m/z = 622.2967. Elemental analysis calculated for C32H48N4O4Ga+CH4O: C
50.72; H 6.71; N 7.17; Ga 8.92%. Found: C 50.51; H 6.68; N 7.08; Ga 9.05%.
Radiochemistry. Radiolabeled 67/68Ga-Galmydar was synthesized using a procedure
described earlier [20] with slight modifications. Briefly, 68Ga was eluted from a generator (Eck-
ert & Ziegler Eurotope; IGG100-50M) using 0.1M HCl, the eluted mixture was passed through
cation exchange column (Phenomenex; Strata-X-C 33 μm Polymeric Strong Cation; 30 mg/
mL) to remove tracer metal impurities, and finally pure 68Ga (370–444 MBq) was eluted with
400 μL of 0.02 M HCl in 98/2 acetone/water [30]. Thereafter, HEPES buffer (pH 5.45, 400 μL)
was added to the eluent mixture, the pH was adjusted to 4.5, mixed with a solution of the hep-
tadentate Schiff-base precursor ligand (50μg) dissolved in ethanol, and heated at 100˚C for 20
min. The reaction was monitored using radio-TLC. Following completion of the reaction, the
reaction mixture was diluted with water (5mL), and pH was adjusted to 7 using 10% NaOH
(5–10 μL). Finally, 68Ga-Galmydar was purified using a C-18 reversed-phase column, employ-
ing the gradient eluent mixture of ethanol and saline (as described above), using radio-HPLC
and also analyzed using radio-TLC (methanol/saline (90/10); Rf = 0.9;>95% purity; radio-
HPLC: Rt = 17.0 min, radiochemical yield: 222–296 MBq (Am: 358–477 MBq/nM), 60%). The
radiotracer was characterized by spiking an unlabeled analytically characterized sample of Gal-
mydar (10 μg) with the 67/68Ga-radiolabeled counterparts, using UV and radio-detectors. The
radiolabeled fraction was concentrated, reconstituted in sterile saline containing 2% ethanol,
and employed for micro-PET imaging and post imaging biodistribution studies.
Bioassays
MicroPET imaging and biodistribution studies.
MicroPET/CT Imaging. All animal procedures were approved by the Washington University
Animal Studies Committee. Imaging and biodistribution studies were performed in Sprague-
PET imaging of DOX-induced cardiotoxicity
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Dawley rats. Five days prior to imaging/biodistribution studies, rats (sex, n = 3) were treated either
with Doxorubicin at a dose of 15 mg/kg) or vehicle (saline). Prior to PET imaging, rats were anes-
thetized with isoflurane (2.0%) via an induction chamber and maintained with a nose cone. Fol-
lowing anesthesia, the rats were secured in a supine position and placed in an acrylic imaging
tray. Following 60 min post intravenous tail-vein administration of 68Ga-Galmydar (250 μL; 2%
ethanol in saline, 5–5.5 MBq), micro-PET static Images were acquired, using a Focus 220 micro-
PET or Inveon PET/CT scanner (Siemens Medical Solutions). PET imaging consisted of a 10-min
acquisition. PET data were stored in list mode, and reconstruction was performed using a
3D-OSEM method with detector efficiency, decay, dead time, attenuation, and scatter corrections
applied. For anatomical visualization, PET images were also co-registered with CT images from
an Inveon PET/CT scanner. ROIs were drawn over the myocardium, and standard uptake values
(SUV) were calculated as the mean radioactivity per injected dose per weight.
Biodistribution Studies. All animal procedures were approved by the Washington Univer-
sity Animal Studies Committee. Following microPET/CT imaging, rats were sacrificed by cer-
vical dislocation. These studies were done in non-perfused rats. Blood samples were obtained
by cardiac puncture, organs then harvested rapidly, and all tissue samples analyzed for γ-activ-
ity using Beckman Gamma 8000 counter. All samples were decay-corrected to the time, the γ-
counter was started. Standard samples were counted with the organs for each animal, and rep-
resent 1% of the injected dose. An additional dose was diluted into milliQ water (100mL) and
aliquots (1mL) were counted with each mouse. Data were quantified as the percentage injected
dose (%ID) per gram of tissue (tissue kBq (injected kBq)–1 (g tissue)–1 x 100).
Cell Culture. Rat cardiomyoblasts (H9c2(2–1)) cells were grown in Dulbecco’s Modified
Eagle Medium (DMEM) supplemented with L-glutamine (2 mM), penicillin/streptomycin
(200 I.U.) and heat-inactivated fetal calf serum (10%). The cells were grown at 37˚C under a
5% CO2 atmosphere.
Fluorescence Imaging Studies. For dose-dependent doxorubicin treatment studies, H9c2
cells were plated onto borosilicate 8-well chambered coverglass (Labtek) and allowed to grow
to approximately 70% confluence at 37˚C under 5% CO2 atmosphere in 200 μL of culture
medium. For assessment of DOX dependent effects, cells were incubated with concentrations
of doxorubicin (0 μg/mL, 1 μg/mL, 5 μg/mL, and 10 μg/mL) for 24 h at 37˚C under continuous
influx of 5% CO2. For evaluating impact of electronegative transmembrane gradients on
uptake profiles of the metalloprobe, cells were also incubated with the Galmydar (20 μM) for
1h at 37˚C either in presence or absence (control) of 130 mM K+ and valinomycin (1μg/mL)
in the media. Prior to fluorescence imaging, cells were incubated with Galmydar (20 μM) for
1h at 37˚C, while maintaining continuous influx of 5% CO2. Cellular accumulation of the Gal-
mydar was assessed using a Nikon Ti-E PFS inverted microscope equipped with a Nikon
40 × 0.3 NA Plan APO objective, Prior H117 ProScan flat top linear encoded stage, and Prior
Lumen 200PRO illumination system with standard DAPI (Eext: 350 nm; Eem: 470 nm): and
FITC (Eext: 495 nm; Eem: 519 nm) filter sets. Images were acquired using a Photometrics Cool-
SNAP HQ2 digital camera and MetaMorph Microscopy and Imaging Analysis Software (ver-
sion 7.7.0.0, Molecular Devices). Images were processed and analyzed using the ImageJ
software package (NIH). Following incubation with Galmydar, cells were visualized and
images were acquired using appropriate filter sets (DAPI excitation and FITC emission). Cel-
lular uptake of Galmydar was then quantified (wherein corrected total cellular fluorescence
(CTCF) = integrated density–(area of selected cell × mean fluorescence of background read-
ings) [31] using protocols described elsewhere [21, 32].
For evaluating a time-dependent Doxorubicin treatment effect, prior to imaging, cells were
incubated with Galmydar (20 μg/mL) following treatments with concentrations of DOX (0 μg/
mL, or 10 μg/mL). Cellular uptake of Galmydar was then monitored using fluorescence
PET imaging of DOX-induced cardiotoxicity
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microscopy over the course of 5 h, and then quantified using protocols described earlier. For
evaluation of Dox-induced superoxide production, H9c2 cells were incubated with DOX (1μg/
mL) for 1h, the extracellular volume was removed, rinsed with PBS (2 × 200 μL), and fresh
media (200 μL) was added. Thereafter, MitoSox (0.5 μM) was added, and cells were incubated
at 37˚C for 15 min. Following incubation, the extracellular volume was removed, rinsed with
PBS (2 × 200 μL), and fresh media (200 μL) was added, thereafter images were acquired, and
cellular uptake was quantified as described above.
Radiotracer Bioassays. Radiotracer uptakes in H9c2 cells were performed in 24-well tissue
culture treated plates. Cells (100,000/well) were plated in media and allowed to recover over-
night. Media was removed from cells and replaced with media containing the desired concen-
trations of 67Ga-Galmydar (74 kBq/mL) using control buffer either in the absence or presence
130 mM K+/valinomycin (1 μg/mL) buffer [33]. Cells were incubated under normal incuba-
tion conditions (37˚C, 5% CO2 atmosphere) for 60 min, and then washed 3× with cold (4˚C)
phosphate buffered saline (without CaCl2 and MgCl2). Cells were then extracted in 1% sodium
dodecyl sulfate with 10 mM sodium borate. Aliquots of the loading solution and 67Ga-Galmy-
dar stock solutions also were obtained for standardizing cellular data with the extracellular
concentration of the tracer. All cell extracts, 67Ga-Galmydar stock solutions, and loading solu-
tion samples were assayed for γ-activity in a well-type sodium iodide γ-counter (Cobra II;
Packard). Protein mass was estimated by the bicinchoninic acid analysis (Pierce Chemical
Co.), using bovine serum albumin as the protein standard. Data are reported as fmol 67Ga-Gal-
mydar (mg protein)−1 (nM0)
−1 as previously described [20, 30, 34, 35] with nM0 representing
the total concentration of 67Ga-complex in the extracellular buffer.
Detection of caspase-3 activation. Caspase-3 activation was measured using the Alexa
Fluor 647 Rabbit Anti-Active Caspase-3 monoclonal antibody (clone C92-6505, BD Biosci-
ences, San Jose, CA) [36]. Both Dox dose- and time-dependent Caspase activation studies
were performed.
For dose-dependent caspase-3 activation studies, H9c2 cells were grown in T150 flasks and
treated with either 0, 1, 5, or 10 μg/mL of doxorubicin for 24 h. Cells were harvested and
washed twice using cold PBS. Cell pellets were resuspended in PBS and stained with a LIVE/
DEAD fixable yellow dead cell stain (Thermo Fisher, Carlsbad, CA). Cells were washed twice
in PBS, fixed and permeabilized using a BD Cytofix/Cytoperm Kit (BD Biosciences, San Jose,
CA) followed by staining with an Alexa Fluor 647 Rabbit Anti-Active Caspase-3 monoclonal
antibody. Samples were analyzed on a flow cytometer (Beckman Coulter Gallios) and data
were analyzed using FlowJo software (TreeStar, Ashland, OR).
For time-dependent caspase-3 activation studies, H9c2 cells were grown in T150 flasks and
treated with either concentrations of 0 or 10 μg/mL of doxorubicin for 1 h and then allowed to
recover for 0–4 days. Caspase activation activity over 0–4 days was evaluated with the flow
cytometer (Beckman Coulter) and quantified as described above.
Statistical Analysis. This imaging study is a proof-of-the concept preliminary study. Due to
limitations of small sample size in this feasibility study, nonparametric test were used for testing
significance of reported data. Wilcoxon or Kruskall-Wallis tests were deployed to examine differ-
ences between groups and Friedman’s Chi-square was used to assess differences within and
between groups, as needed. SASv9.4 was used to conduct data analysis (SAS Institute, Cary, NC).
Results and discussion
Doxorubicin has been known to act as an antitumor agent primarily by intercalation into
DNA and inhibiting topoisomerase II (TOP2) in fast-proliferating cancer cells, thus inducing
cancer cell death [37]. Importantly, DOX-induced cardiotoxicity involves apoptosis or other
PET imaging of DOX-induced cardiotoxicity
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forms of cell death in cardiomyocytes, resulting in loss of functional myocytes and irreversible
heart injury. However, the mechanism for DOX-mediated cardiotoxicity appears to be separa-
ble from its therapeutic mode of action due to 2 factors: a) cardiomyocytes are generally not
replicative, and b) Top2α, the primary target of doxorubicin, is not expressed in quiescent
cells, and is undetectable in heart tissues [38, 39]. Therefore, various mechanisms for DOX-
induced cardiomyopathy have been proposed, such as generation of reactive oxygen species
(ROS) [40, 41], impaired mitochondrial function, disruption of Ca2+ homeostasis, and altered
gene and protein expression that triggers cell death [42, 43]. Furthermore, it has also been
shown that changes in mitochondrial redox state, and membrane potential could precede
DOX-induced cell death [44, 45].
Previously, we reported that Galmydar is a fluorescent probe, and its uptake within human
breast carcinoma cells is a net function of transporter-mediated efflux at plasma membrane
and negative transmembrane electrochemical gradients-mediated influx present at plasma-
and mitochondrial membranes (Fig 2)[21]. To assess its accumulation profiles, and intracellu-
lar localization at a single cell level, Galmydar was incubated with rat cardiomyoblasts (H9c2)
either in presence or absence of mitotracker Red CM-H2XRos (25 nM; a well- validated posi-
tive control for mapping mitochondria) [46–48] at 37˚C for 60 min, and uptake was evaluated,
using live cell imaging. Galmydar penetrated cells and showed stable retention within H9c2
cells. Importantly, the localization of Galmydar within mitochondria of H9c2 cells also
mapped closely with that of mitotracker Red (Fig 2A) thereby confirming its intracellular
localization within mitochondria of H9c2 cells. To assess whether or not, cellular accumulation
profiles using a fluorescent read out are in accord with that of radiotracer bioassay, 68Ga-Gal-
mydar was also incubated in H9c2 cells at 37˚C for 60 min, and the cell uptake was quantified
using methodologies described earlier. While the optical imaging allows investigations of
uptake profiles for the metalloprobe at a single cell level, the radiotracer assay enables quantifi-
cation of accumulation of a given probe in population of cells under identical conditions. To
assess radiotracer uptake profiles, 68Ga-Galmydar was incubated in H9c2 cells for 60 min, and
the radiotracer uptake was quantified by normalizing the counts to cell protein. Importantly,
68Ga-Galmydar permeated H9c2 cells, demonstrated very high levels of the radiotracer uptake
(745±112 fmol (mg P)−1 (nM0)−1), and the radiotracer uptake profiles match fairly well with
that of an optical readout (Fig 2B). In the absence of Pgp expression in H9c2 cells, 68Ga-Gal-
mydar uptake could also be beneficial in deducing mitochondrial function. Therefore, we pos-
tulate that 68Ga-Galmydar could likely provide an earliest readout about the status of
mitochondrial potential and resultant downstream impact on initiation of apoptosis in vivo.
Fig 2. (A) Cellular accumulation of Galmydar and demonstration of its intracellular localization in mitochondria via correlation with Mito-Tracker:
Images were acquired using a 60 × objective (all panels represent same magnification) in live H9c2(2–1) cells following 30 min treatment with Galmydar
(20 μM) and MitoTracker Red CM-H2XRos (25 nM). A: DIC; B: Uptake of Galmydar; C: Uptake of MitoTracker Red; D: Merge of B & C. (B) Cellular
accumulation of 67Ga-Galmydar in rat cardiomyoblasts H9c2(2–1). Shown is a net uptake at 90 minutes (fmol nM0
−1 mg protein−1) using the control media.
The bar represents the mean of 4 determinations; the line above the bar denotes ±SD.
https://doi.org/10.1371/journal.pone.0215579.g002
PET imaging of DOX-induced cardiotoxicity
PLOS ONE | https://doi.org/10.1371/journal.pone.0215579 May 23, 2019 7 / 19
Earlier, we have shown (through quantitative pharmacokinetic studies) that 68Ga-Galmydar
penetrates myocardium of mice and rat, minutes post tail-vein injection. While rapidly excret-
ing from blood pool within minutes to nearly background levels, 68Ga-Galmydar also indi-
cated a high extraction and stable retention in myocardium of mice and rat as a function of
time (5 min through 2 h) post tai-vein injection [20]. These data indicated the potential utility
of 68Ga-Galmydar PET imaging to enable interrogation of heart function in vivo. Additionally,
TACs from dynamic PET scans (following tail-vein injections of the radiotracer) showed heart
uptake and stable retention in rats as a function of time (up to 70 min, data not shown). To fur-
ther assess potential of 67/68Ga-Galmydar to serve as a molecular imaging probe for assessment
of DOX-induced cardiotoxicity in vivo, 67/68Ga-Galmydar was synthesized through a ligand-
exchange reaction using procedures described earlier [20], purified, and analyzed using radio-
HPLC, Fig 3). Finally, 67/68Ga-Galmydar was reconstituted in saline containing ethanol (2%),
and deployed for either cell uptake assay or microPET/CT imaging experiments. Prior to
imaging, rats were pretreated either with intravenous administration of DOX (15 mg/kg) or
vehicle (5% ethanol in saline) for 5 days. Following treatments, micro-PET static scans (10
min acquisition; 60 min post tail-vein administration of 68Ga-Galmydar; Fig 4A) demon-
strated a 1.91-folds lower retention in hearts of DOX-treated (Standard Uptake Value; SUV:
0.92, n = 3) rats compared with their vehicle treated counterparts (SUV: 1.76, n = 3), (Fig 4B).
For confirmation of PET data, post-imaging quantitative biodistribution studies were also per-
formed. All rats were sacrificed by cervical dislocation, organs excised, counted for γ activity,
and the activity was normalized to % injected dose (ID) and weight. The post imaging pharma-
cokinetic data demonstrated heart retention values of 2.02 folds lower for DOX treated (%ID/
g; DOX: 0.44 ± 0.1, n = 3) rats compared to their vehicle treated counterparts (Vehicle Control:
0.89 ± 0.03, n = 3, p = 0.04), Fig 5, thus further supporting micro-PET imaging data in vivo.
Fig 3. Radio-HPLC data for 67Ga-Galmydar (Blue) and 68Ga-Galmydar (Red) spiked with an unlabeled Galmydar (Green). The
peaks are off-set for clarity.
https://doi.org/10.1371/journal.pone.0215579.g003
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The normal function of mitochondria is essential for controlling inter-dependent biochem-
ical pathways, such as apoptotic signaling, intracellular Ca+2 regulation, and ROS generation.
Although the exact mechanism (s) of DOX-induced cardiotoxicity have been intensely studied,
the formation of free-radicals following binding to iron continues to be the main mode of
action [49]. Other mechanisms involve direct DNA damage, blocking of mitochondrial ade-
nine-triphosphate generation, and release of apoptotic proteins (caspases). Importantly, myo-
cardium is more susceptible to free-radical damage compared with other tissues due to less
abundance of free-radical scavenging enzymes (superoxide dismutase and catalase) in addition
to suppression of glutathione peroxidase [50]. Over the past decades, the degeneration of mito-
chondria has also been attributed to modification of multi-molecular complex (mitochondrial
permeability transition pore, mPTP), a high conductance channel in the inner membrane of
mitochondria, which is permeable to solutes up to 1.5 kDa. Overall, the mPTP is a Ca+2, pH,
redox-, and voltage sensitive channel. Thus opening of the mPTP can either be transient thus a
reversible event or a long-lasting process. While the transient opening regulates critical physio-
logical processes, such as intracellular Ca+2 homeostasis, NAD+ trafficking, and production of
transient ROS[51, 52], it is typically not associated with cell death. However, the long-lasting
opening of mPTP is normally considered irreversible, thus increases mitochondrial permeabil-
ity to ions, and solutes, and resultant loss of electrochemical gradients, thereby leading to
depolarization of mitochondrial potential, reduction in ATP levels, increase in ROS produc-
tion, Ca+2 release, vacuolization and swelling of mitochondria thus eventually mediating pro-
gression to cell death [53–55]. Overall, these observations indicate that DOX-mediated activity
likely result in a depolarization of mitochondrial potential and subsequent caspase activation
[22].
To further understand possible biochemical processes driving the resulted decreased reten-
tion of the radiotracer within the rat myocardium, the cellular accumulation of Galmydar was
performed in cultured H9c2 rat cardiomyoblasts. For cell uptake evaluations, both radiotracer-
and live-cell fluorescence imaging [21, 32] studies were performed. To accomplish this objec-
tive, we evaluated uptake profiles of Galmydar in cultured H9c2 rat cardiomyoblasts using
Fig 4. (A) Micro-PET/CT Imaging. Sprague-Dawley rats were injected intravenously with 68Ga-Galmydar and static PET images were acquired for 10 min, 60
min post tail-vein injection. Top Panel: Control Rat; Lower Panel: DOX (15mg/kg, 5 days prior to imaging)-treated Rat. Similar results were obtained in 3
independent experiments. (B) SUV analysis of 68Ga-Galmydar uptake in hearts of SD rats (mean ± SD, n = 3).
https://doi.org/10.1371/journal.pone.0215579.g004
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fluorescence microscopy, and subsequent quantification was performed. Of note, Galmydar is
a fluorescent molecule (Eex: 375 nm, Eemis = 485 nm) [30]. Because DOX causes dose-depen-
dent cardiomyopathy in cancer patients[40], we evaluated cell uptake of Galmydar as function
of DOX concentration, using live cell fluorescence imaging. For investigations, H9c2 cells
were treated with increasing concentration of DOX (1 μg/mL, 5 μg/mL, and 10 μg/mL)[44] for
24 h at 37˚C under a continuous flux of 5% CO2. After 24h, cells were recovered in fresh
growth media, and then incubated with Galmydar (20 μM) for 1 h at 37˚C under 5% CO2, and
cellular accumulation was analyzed under identical conditions, using a Nikon Ti-E PFS
inverted microscope. Galmydar demonstrated cell uptake profiles mediated by DOX-dose (Fig
6), wherein probe accumulation deceased as a function of increased DOX-dose (1.0-fold
depression in 1μg/mL, 1.3-fold depression in 5 μg/mL, and 5.2-fold depression in 10 μg/mL, H
(3, N = 3) 9.45, p = 0.02, Kruskal-Wallis). To further evaluate uptake kinetics of Galmydar
(20 μM) as a function of time, H9c2 cells were also plated and incubated with DOX or vehicle
at 37˚C under a continuous flux of 5% CO2, recovered to fresh growth media, immediately
treated with Galmydar (20 μM) and monitored for 5 h under identical conditions, using a
Nikon Ti-E PFS inverted microscope. Over the course of 5 h, the cultured rat myocardium
Fig 5. Post-imaging biodistribution data (%ID/g) for 68Ga-Galmydar in rats treated either with DOX (15mg/kg; 5 days prior to imaging) or vehicle as a
control (mean ± SD, n = 3). Using Wilcoxon 2-sample tests, and one-sided, the p values were obtained for uptake in each organ (Brain: z = 1.75, p = 0.07;
Blood: z = 1.74, p = 0.04; Fat: z = 1.31, p = 0.10; Heart: z = 1.75, p = 0.04; Lung: z = 0.44, p = 0.34; and muscle: z = 1.31, p = 0.10).
https://doi.org/10.1371/journal.pone.0215579.g005
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cells exhibited a gradual depression in cellular uptake and retention of Galmydar (Fig 7; up to
8.2-fold difference compared to their untreated cells after 5 h, p = 0.09, Friedman’s chi-square),
thus indicating the sensitivity of the probe to map changes at the level of the mitochondria
resulting from DOX treatment, which in turn likely result from depolarization of the mito-
chondrial potential. These findings are consistent with literature precedents, wherein DOX
treatment has been shown to alter mitochondrial redox potentials, thus depolarizing mito-
chondria, and elevating matric Ca2+ and ROS production in 30 minutes [15]. Furthermore,
the reduction of DOX in the mitochondria results in the production of its semiquinone form,
which reacts with iron, oxygen and hydrogen peroxide to produce ROS [15]. It has been postu-
lated that DOX treatments alter mitochondrial redox potentials towards a more oxidized state,
depolarize mitochondria, elevate matrix calcium levels, and elevate ROS production. To evalu-
ate, whether ROS production in DOX-treated H9c2 cells is indeed mediated by superoxide
production, live-cell imaging was performed, and fluorescence signal was quantified (Fig 8) as
a function of time following DOX-treatments. MitoSox (a well validated fluorescent probe to
monitor superoxide production in mitochondria [56, 57]) signal was enhanced by 1.5–2.6
Fig 6. DOX induced cardiomyopathy in rat cardiomyocytes cells. H9c2 cells were treated with DOX (0, 1, 5 and 10 μg/mL) for 24h and uptake of Galmydar
(20 μM, 60 min) was determined using fluorescence imaging. Corrected Total Cell Fluorescence (CTCF) = Integrated Density–(Area of selected cell X Mean
fluorescence of background readings); (mean ± SEM, H (3, N = 3) 9.45, p = 0.02, Kruskal-Wallis).
https://doi.org/10.1371/journal.pone.0215579.g006
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folds, 4–6 h following Dox-treatments of H9c2 cells (Fig 8) thus demonstrating a time-depen-
dent pharmacological response consistent with production of superoxide in the mitochondria.
Importantly, while decreased retention of Galmydar was evident through depolarization of the
mitochondrial potential after 1h post incubation (Fig 7), the superoxide production was found
to be observed after 3h post-treatment (Fig 8) thus indicating mitochondrial depolarization
precedes superoxide production under these conditions. The mitochondria respond to this
excessive oxidative stress, depolarization, and altered redox states by formation of a mitochon-
drial permeability transition pore (MPTP). The MPTP allows Cytochrome c to leak out, which
triggers a cascade leading to the activation of the effector caspase-3 and thereby inducing apo-
ptosis [15]. To evaluate whether or not Galmydar imaging provides an upstream indication of
induction of apoptotic pathways as mitochondria begin to depolarize, flow cytometric assays
were also performed. Upon treatment with increasing dosages of doxorubicin, flow cytometry
revealed increasing caspase-3 activation, inversely proportional to the Galmydar uptake
depression observed in fluorescence microscopy studies. Furthermore, caspase-3 activation
was shown to progressively increase over the course of 4 days after doxorubicin treatment,
indicating that Galmydar demonstrated sensitivity to map mitochondrial defects that precede
the mitochondrial apoptotic pathway involving effector caspase-3 (Fig 9). This observation is
further supported by the findings from the biodistribution studies, which suggests a possible
reduction in Galmydar retention within the rat heart parenchyma following single dose treat-
ment (5 days earlier) of doxorubicin (χr
2 (1, N = 11) = 7.47, p = 0.19, Friedman’s chi-square).
Fig 7. DOX induced cardiomyopathy in rat cardiomyocytes cells. H9c2 cells were treated with DOX (0 and 10 μg/
mL) for 0–5 h and uptake of Galmydar (20μM, 60 min) was determined using fluorescence imaging. Corrected Total
Cell Fluorescence (CTCF) = Integrated Density–(Area of selected cell × Mean fluorescence of background readings);
(mean ± SEM, χr2 (1, N = 35) = 2.88, p = 0.09, Friedman’s chi-square).
https://doi.org/10.1371/journal.pone.0215579.g007
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To further access whether or not the decreased uptake of Galmydar in H9c2 cells is indeed
resulting from depolarization of mitochondrial potential at a single cell level, Galmydar was
incubated in H9c2 cells in the media either in presence or absence of valinomycin (1μg/mL),
an ionophore and high potassium (130 mM KCl) concentration at 37˚C for 1h under a contin-
uous flux of 5% CO2; and cell uptake was quantified as corrected total cellular fluorescence
(CTCF). Valinomycin is a dodecadepsipeptide, and an ionophore which facilitates transfer of
K+ across the cellular membranes thus resulting in dissipation of both plasma-and mitochon-
drial electrochemical gradients. Compared with control media (CTCF = 7.94× 106 ± 3.17×
105), Galmydar uptake was reduced (CTCF = 1.6 × 106 ± 1.5× 105) to approximately 20% of
control in H9c2 cells following incubation in the media containing valinomycin in high K+
concentrations; Fig 10A thus indicating a response of the metalloprobe to depolarization of
the electrochemical gradients. Similar uptake profiles were also observed using 67Ga-Galmydar
155±17 fmol (mg P)−1 (nM0)−1, <20% of control (745±112 fmol (mg P)−1 (nM0)−1), the
SPECT counterpart described earlier (Fig 10B). Combined data indicate that significant por-
tion of uptake of the metalloprobe is driven by its response to electronegative membrane
potentials, and also demonstrates its potential to monitor depolarization of the mitochondrial
potential in cellulo.
Fig 8. DOX induced superoxide production in rat cardiomyocytes cells. H9c2 cells were treated with DOX (1μg/mL) for 60
min at 37˚C, extracellular space was rinsed with PBS (2 times), replaced with media, incubated with MitoSox (0.5μM) at 37˚C
for 15 min, and intracellular uptake was analyzed using fluorescence imaging. Corrected Total Cell Fluorescence (CTCF) =
Integrated Density–(Area of selected cell × Mean fluorescence of background readings); (mean ± SEM; p> 0.01).
https://doi.org/10.1371/journal.pone.0215579.g008
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Conclusions
Following a single dox treatment of rats, microPET/CT imaging shows 2-fold lower retention
of 68Ga-Galmydar in myocardium compared with their vehicle treated control counterparts.
SUV values obtained from micro-PET/CT imaging studies also correlated with myocardium
uptake and retention of the tracer using post-imaging quantitative biodistribution studies.
Additionally, treatments of myocardial cells with doxorubicin resulted in gradual decrease of
Galmydar uptake and retention within mitochondria of H9c2 cells in a dose-dependent and
time-dependent manner. Noticeably, this decrease of Galmydar accumulation, and retention
in H9c2 cells is also consistent with depolarization of electronegative membrane potentials
and activation of caspase-3 activity resulting in doxorubicin-induced cardiotoxicity and cell
death. Given that mitochondrial depolarization precedes detection of elevated superoxide pro-
duction within H9c2 cells, and Galmydar accumulation within these cells is a net function of
mitochondrial energetics, these findings suggest that 68Ga-Galmydar imaging could potentially
provide an early read-out of apoptotic processes, wherein mitochondrial potential undergoes
Fig 9. DOX induced caspase-3 activation in rat cardiomyocytes cells. H9c2 cells were treated with DOX (0 and 10 μg/mL) for 1h, recovered for
0–4 days and caspase-3 activation was determined using flow cytometry (χr
2 (1, N = 11) = 7.47, p = 0.19, Friedman’s chi-square).
https://doi.org/10.1371/journal.pone.0215579.g009
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either transient or permanent changes thus leading to impairment in mitochondrial function.
Combined data indicate that decreased uptake profiles of the radiotracer observed, following
treatments with DOX are in accord both in vivo and in cellulo profiles at a single cell level; and
are likely attributed to impairment of mitochondrial potential[20, 32]. However, these data
need to be further ascertained with other functional myocardium viability methodologies
using either MRI or US in vivo. While these studies provide preliminary evaluation of 68Ga-
Galmydar potential to monitor DOX-induced cardiotoxicity 5-d post administration of a sin-
gle dose, it is also evident from Fig 8 that significant activation of caspase 3 takes place in H9c2
cells by 2nd day of the DOX-treatment. Therefore, additional micro-PET imaging studies are
needed to evaluate sensitivity of 68Ga-Galmydar to investigate DOX-induced cardiotoxicity in
vivo at earlier time-points, and correlate imaging data with histochemical staining. Although
mitochondrial energetics are altered upstream prior to either elevated superoxide production
or drug-induced upregulation of caspase-3 activation, it is conceivable that DOX treatments
could have some effect on perfusion thus partially contributing to the decreased retention of
68Ga-Galmydar in heart, therefore further studies are needed to ascertain contribution of per-
fusion effects (if any) following DOX treatments, using FDA approved tracer, such as
11N-NH3. Following further biochemical validations and functional correlations with other
imaging modalities such as MRI, 68Ga-Galmydar could provide a specific and sensitive nonin-
vasive molecular imaging technique for monitoring mitochondrial impairment, thereby
enabling stratification of therapeutic choices for patients undergoing chemotherapeutic treat-
ment in general, and DOX-treatment in particular. Further investigations (in rat and rabbit
Fig 10. (A) Cellular accumulation of Galmydar in rat cardiomyoblasts H9c2(2–1) either in control buffer or in presence of 130 mM K+ buffer containing
valinomycin (1 μg/mL), the potassium ionophore. Shown is a net uptake at 60 minutes (CTCF) derived from live-cell imaging data. The bar represents the
mean of 4 determinations; the line above the bar denotes ±SD. Note dissipation of prevalent electronegative gradients on membranes resulting from influx of
K+ into cells leading to 80% lower uptake (red bar) compared with that of control (blue) under identical conditions. (B) Cellular accumulation of 67Ga-
Galmydar in rat cardiomyoblasts H9c2(2–1) either in control buffer or in presence of 130 mM K+ buffer containing valinomycin (1 μg/mL), the
potassium ionophore. Shown is a net uptake at 90 minutes. Data are reported represented as fmol of 67Ga-Galmydar (mg protein)−1 (nM0)
−1, wherein nM0
representing the total concentration of 67Ga-complex in the extracellular buffer. The bar represents the mean of 4 determinations; the line above the bar
denotes ±SD. Note uptake profiles of the radiotracer correlate with that of fluorescence live cell imaging.
https://doi.org/10.1371/journal.pone.0215579.g010
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models) with other chemotherapeutics (both traditional drugs and antibodies) that are suscep-
tible to similar mode of action, and likely to induce cardiotoxicity, are underway.
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